secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001104659-23-086368
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q2 net loss narrows to $6.6M; TAVALISSE sales up 15% YoY to $21.3M
------------------------------------------------------------------------

- Q2 net loss $6.6M ($0.04/sh) vs $13.5M loss in Q2 2022; total revenue $26.9M.
- TAVALISSE net product sales $21.3M (+15% YoY); REZLIDHIA sales $2.6M with 77% sequential bottle growth.
- Cash, equivalents & investments $64.4M at June 30, up from $58.2M at Dec 31, 2022.
- R289 Phase 1b in LR-MDS completed cohort 2 enrollment; R552 Phase 2a in RA initiated by Eli Lilly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/0001104659-23-086368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/tm2322488d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer